http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019060536-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd47318319f20f7f99d9fef1fd3e511b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 |
| filingDate | 2018-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3d8ad206f8ddce84cca5393d5eaa348 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6630818aed76605112c1f8ca0ecc2a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2fb2a795b4c7ec9c0d9309a8fd1e9ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebc9c6a2feff48f19f37153ae8c833a2 |
| publicationDate | 2019-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2019060536-A1 |
| titleOfInvention | CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDEN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES |
| abstract | The present invention relates to co-crystalline forms of ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-dihydro-1H-inden-1-ylamino] -7H-pyrrolo [2, 3-d] pyrimidin-7-yl} -2-hydroxycyclopentyl) methylsulfamate of formula ( I ). The invention also relates to methods for producing (15S, 2S, 4R) -4- {4 - [(1S) -2,3-dihydro-1H-inden-1-ylamino] -7H-pyrroloacocrystalline forms of [2,3-d] pyrimidin-7-yl} -2-hydroxycyclopentyl) methylsulfamate of formula ( I ). The invention also relates to the pharmaceutical use of a co-crystalline form as an activating enzyme inhibitor E1, as well as a pharmaceutical composition comprising said co-crystalline form. A method of treatment comprising administering a co-crystalline form of ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-dihydro-1H-inden-1-ylamino] 7H-pyrrolo [2,3-d] pyrimidin-7-yl} -2-hydroxycyclopentyl) methylsulfamate of formula ( I ) is further described. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11124519-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022112951-A1 |
| priorityDate | 2017-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 452.